作为B细胞非霍奇金淋巴瘤的潜在治疗点的类蛋白质
Dan Zou1, Sitong Feng1, Bowen Hu1
1The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
Cell & bioscience
|November 23, 2024
概括
代蛋白 (BRD) 蛋白质是B细胞非霍奇金淋巴瘤 (B-NHL) 的关键表观遗传调节者. 针对这些BRD蛋白质为B-NHL患者提供了一个有前途的治疗策略,特别是那些复发或耐药疾病患者.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 血液学 血液学 血液学
背景情况:
- B细胞非霍奇金淋巴瘤 (B-NHL) 是一种异质恶性瘤,复发/耐药病例的预后不佳.
- 表观遗传失调与血液恶性瘤有关,引发了人们对表观遗传疗法的兴趣.
研究的目的:
- 审查odomain (BRD) 蛋白在B-NHL病原发生中的作用.
- 总结一下B-NHL的BRD蛋白向疗法的最新进展.
- 评估BRD蛋白质作为B-NHL的治疗点的潜力.
主要方法:
- 对B-NHL中BRD蛋白抑制剂和降解剂的临床前和临床研究的综述.
- 对各种BRD蛋白向剂的作用机制的分析.
- 综合目前关于BET抑制剂,BET降解剂和非BET BRD 抑制剂疗效的证据.
主要成果:
- odomain (BRD) 蛋白质是参与B-NHL的关键表观遗传调节者.
- 无论是BET抑制剂还是降解剂都表现出抗瘤活性,降解剂在临床前模型中表现出更高的疗效.
- 非BET BRD蛋白抑制剂在B-NHL中也表现出治疗潜力.
结论:
- 在B-NHL中,BRD蛋白代表了关键的表观遗传调节者.
- 准BRD蛋白,包括BET家族成员和其他人,为B-NHL提供了一个可行的治疗途径.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K


